The Latest Breaking News from BMRN

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors might consider adding three well-positioned biotech stocks such as Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD), for potential gains. Learn more….

The biotech market offers great investment potential due to innovative advancements in genetic profiling, biologics, CRISPR technology, and rare disease treatments driving strong demand and growth. Therefore, investing in strong biotech stocks like Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), and United Therapeutics (UTHR) could be wise. Read on.

The biotech industry's future appears bright due to advancements in biochemical and pharma technologies, AI integration, rising targeted treatments, and increased R&D spending driving breakthroughs. Therefore, it could be wise to invest in undervalued biotech stocks such as Harmony Biosciences Holdings (HRMY), United Therapeutics (UTHR), and BioMarin Pharmaceutical (BMRN). Read…

Vertex Pharmaceuticals has outperformed the Nasdaq over the past year, and analysts remain moderately bullish about the stock's prospects.

The biotech sector is primed for growth, fueled by numerous advancements in genetic engineering and rising investment in research and development of personalized medicine. Hence, quality biotech stocks, BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), and Corcept Therapeutics (CORT) with sky-high price targets might be solid buys. Read more….

This year, the biotech industry anticipates a resurgence with increased M&A, FDA approvals, and AI-driven innovations. Given the industry’s rosy prospects, biotech stocks BioMarin Pharmaceutical (BMRN), ANI Pharmaceuticals (ANIP), and Genmab A/S (GMAB), gaining significant altitude and interest, could be ideal buys. Read on.

The biotech industry’s growth prospects look promising due to innovative drugs and therapies, government initiatives, and technological advancements. Therefore, investors could consider buying fundamentally strong biotech stocks BioMarin Pharmaceutical (BMRN), Illumina (ILMN), and Harmony Biosciences (HRMY). These stocks are B-rated (Buy) in our proprietary rating system. Read on.

Robust government support coupled with rapid tech advancements is bolstering the biotech sector. Hence, investors eyeing growth might buy fundamentally solid biotech stocks Theratechnologies (THTX), Equillium (EQ), and BioMarin Pharmaceutical (BMRN), with massive growth potential. Read on.

The biotechnology industry is experiencing significant growth, fueled by government initiatives, rising investments and tech advancements. Therefore, it could be wise to consider fundamentally strong biotech stocks Shionogi & Co (SGIOY), Equillium (EQ), and BioMarin Pharmaceutical (BMRN), which are making major moves on wall street. Read more.